Hans Eiskjær
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hans Eiskjær has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Adelina Yafasova
Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
1 shared publication - Anna Margrethe Thøgersen
Department of Cardiology, Aalborg University Hospital, 9000 Aalborg, Denmark
1 shared publication - Axel Brandes
Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark , Finsensgade 35, Esbjerg 6700
1 shared publication Brian Bridal Løgstrup
Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark
1 shared publication- Christian Hassager
Department of Cardiology Copenhagen University Hospital—Rigshospitalet Copenhagen Denmark
1 shared publication - Christian Torp-Pedersen
Copenhagen University Hospital, Steno Diabetes Center Copenhagen Herlev Denmark
1 shared publication
Latest Publications
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (9) , 838-848
Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial
Background: Men and women may respond differently to certain therapies for heart failure with reduced ejection fraction, including implantable cardioverter defibrillators (ICD). In an extended follow-up study of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality), adding 4 years of additional follow-up, we examined the effect of ICD implantation according to sex. Methods: In the DANISH trial, 1116 patients with nonischemic systolic heart failure were randomized to receive an ICD (N=556) or usual clinical care (N=550). The primary outcome was all-cause mortality. Results: Of the 1116 patients randomized in the DANISH trial, 307 (27.5%) were women. During a median follow-up of 9.5 years, women had a lower associated rate of all-cause mortality (hazard ratio [HR], 0.60 [95% CI, 0.47–0.78]) cardiovascular death (HR, 0.62 [95% CI, 0.46–0.84]), nonsudden cardiovascular death (HR, 0.59 [95% CI, 0.42–0.85]), and a numerically lower rate of sudden cardiovascular death (HR, 0.70 [95% CI, 0.40–1.25]), compared with men. Compared with usual clinical care, ICD implantation did not reduce the rate of all-cause mortality, irrespective of sex (men, HR, 0.85 [95% CI, 0.69–1.06]; women, HR, 0.98 [95% CI, 0.64–1.50]; Pinteraction=0.51). In addition, sex did not modify the effect of ICD implantation on sudden cardiovascular death (men, HR, 0.57 [95% CI, 0.36–0.92]; women, HR, 0.68 [95% CI, 0.26–1.77]; Pinteraction=0.76). Conclusions: In patients with nonischemic systolic heart failure, ICD implantation did not provide an overall survival benefit, but reduced sudden cardiovascular death, irrespective of sex. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00542945.
- 1 September 2022
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 15 (9) , 838-848
Efficacy of Implantable Cardioverter Defibrillator in Nonischemic Systolic Heart Failure According to Sex: Extended Follow-Up Study of the DANISH Trial
Background: Men and women may respond differently to certain therapies for heart failure with reduced ejection fraction, including implantable cardioverter defibrillators (ICD). In an extended follow-up study of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients With Non-Ischemic Systolic Heart Failure on Mortality), adding 4 years of additional follow-up, we examined the effect of ICD implantation according to sex. Methods: In the DANISH trial, 1116 patients with nonischemic systolic heart failure were randomized to receive an ICD (N=556) or usual clinical care (N=550). The primary outcome was all-cause mortality. Results: Of the 1116 patients randomized in the DANISH trial, 307 (27.5%) were women. During a median follow-up of 9.5 years, women had a lower associated rate of all-cause mortality (hazard ratio [HR], 0.60 [95% CI, 0.47–0.78]) cardiovascular death (HR, 0.62 [95% CI, 0.46–0.84]), nonsudden cardiovascular death (HR, 0.59 [95% CI, 0.42–0.85]), and a numerically lower rate of sudden cardiovascular death (HR, 0.70 [95% CI, 0.40–1.25]), compared with men. Compared with usual clinical care, ICD implantation did not reduce the rate of all-cause mortality, irrespective of sex (men, HR, 0.85 [95% CI, 0.69–1.06]; women, HR, 0.98 [95% CI, 0.64–1.50]; Pinteraction=0.51). In addition, sex did not modify the effect of ICD implantation on sudden cardiovascular death (men, HR, 0.57 [95% CI, 0.36–0.92]; women, HR, 0.68 [95% CI, 0.26–1.77]; Pinteraction=0.76). Conclusions: In patients with nonischemic systolic heart failure, ICD implantation did not provide an overall survival benefit, but reduced sudden cardiovascular death, irrespective of sex. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00542945.
- 27 July 2021
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 55 (5) , 300-307
Burden of arrhythmia and silent ischemia in heart transplant patients with cardiac allograft vasculopathy
The incidence of sudden cardiac death (SCD) following heart transplantation (HTx) accounts for approximately 10% of post-HTx deaths. Ischemia, brady- and tachy-arrhythmias caused by rejection and cardiac allograft vasculopathy (CAV) seem related to SCD. Hence, we aimed to investigate the relation between CAV, arrhythmias and silent ischemia in long-term HTx patients. Methods. 49 HTx patients were included. Patients were CAV classified in accordance with guidelines from the International Society of Heart and Lung Transplantation. Patients were divided into predefined CAV groups (CAV 0, CAV 1, CAV 2 + 3). Incidences of arrhythmia and silent ischemia were detected by 48-h electrocardiogram monitoring and analyzed blinded to CAV-status. Results. Median time since transplantation was 9 years [IQR 4–14]. We observed a higher incidence of non-sustained ventricular tachycardia (NSVT) in CAV 2 + 3 patients than CAV 0 and 1 patients (p = .01). Likewise, isolated premature ventricular complexes (PVC) (p = .01) and PQ-interval prolongation (p = .01) were more frequent in CAV 2 + 3 patients than CAV 0 and 1 patients. Silent ischemia was only observed among CAV 3 patients (p = .04). We saw no significant difference in the incidence of supraventricular tachycardia among CAV groups (p = .21). Likewise, no difference in the right bundle branch block was observed (p = .68). Conclusion. NSVT was associated with CAV status in long-term HTx patients. Patients with moderate to severe CAV showed higher incidences of PVCs and PQ-interval prolongation than patients with mild or no CAV. Silent ischemia was only seen in patients with severe CAV.
- 27 July 2021
- Published by Taylor & Francis in Scandinavian Cardiovascular Journal
- Vol. 55 (5) , 300-307
Burden of arrhythmia and silent ischemia in heart transplant patients with cardiac allograft vasculopathy
The incidence of sudden cardiac death (SCD) following heart transplantation (HTx) accounts for approximately 10% of post-HTx deaths. Ischemia, brady- and tachy-arrhythmias caused by rejection and cardiac allograft vasculopathy (CAV) seem related to SCD. Hence, we aimed to investigate the relation between CAV, arrhythmias and silent ischemia in long-term HTx patients. Methods. 49 HTx patients were included. Patients were CAV classified in accordance with guidelines from the International Society of Heart and Lung Transplantation. Patients were divided into predefined CAV groups (CAV 0, CAV 1, CAV 2 + 3). Incidences of arrhythmia and silent ischemia were detected by 48-h electrocardiogram monitoring and analyzed blinded to CAV-status. Results. Median time since transplantation was 9 years [IQR 4–14]. We observed a higher incidence of non-sustained ventricular tachycardia (NSVT) in CAV 2 + 3 patients than CAV 0 and 1 patients (p = .01). Likewise, isolated premature ventricular complexes (PVC) (p = .01) and PQ-interval prolongation (p = .01) were more frequent in CAV 2 + 3 patients than CAV 0 and 1 patients. Silent ischemia was only observed among CAV 3 patients (p = .04). We saw no significant difference in the incidence of supraventricular tachycardia among CAV groups (p = .21). Likewise, no difference in the right bundle branch block was observed (p = .68). Conclusion. NSVT was associated with CAV status in long-term HTx patients. Patients with moderate to severe CAV showed higher incidences of PVCs and PQ-interval prolongation than patients with mild or no CAV. Silent ischemia was only seen in patients with severe CAV.
- 1 October 2018
- Vol. 180
[Treatment of heart failure in patients with reduced left- ventricular ejection fraction].
Treatment of heart failure with reduced ejection fraction has undergone an enormous development over the latest three decades resulting in lower mortality. Standard treatment now includes use of angiotensin-converting-enzyme (ACE)-inhibitors, beta blockers and mineralocorticoid receptor antagonists. Diuretics are still the cornerstone in the symptomatic treatment of fluid retention. Combined angiotensin II receptor blockade and neprilysin inhibition is a new treatment option instead of ACE-inhibition for selected patients. Cardiac resynchronisation therapy and prophylactic implantable cardiac defibrillators further reduce mortality.
- 1 October 2018
- Vol. 180
[Treatment of heart failure in patients with reduced left- ventricular ejection fraction].
Treatment of heart failure with reduced ejection fraction has undergone an enormous development over the latest three decades resulting in lower mortality. Standard treatment now includes use of angiotensin-converting-enzyme (ACE)-inhibitors, beta blockers and mineralocorticoid receptor antagonists. Diuretics are still the cornerstone in the symptomatic treatment of fluid retention. Combined angiotensin II receptor blockade and neprilysin inhibition is a new treatment option instead of ACE-inhibition for selected patients. Cardiac resynchronisation therapy and prophylactic implantable cardiac defibrillators further reduce mortality.